Krystal Biotech (KRYS) Net Margin (2023 - 2026)

Krystal Biotech (KRYS) has 4 years of Net Margin data on file, last reported at 48.06% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 754.0% year-over-year to 48.06%; the trailing twelve-month figure through Mar 2026 stood at 53.93% (up 1676.0% YoY), and the FY2025 full-year result was 52.64%, up 2195.0% from the prior year.
• Net Margin was little changed at 48.06% in Q1 2026, from 47.98% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 943.75% in Q3 2023 to a low of 2.06% in Q1 2024.
• A 4-year average of 120.78% and a median of 40.52% in 2025 frame the typical range for Net Margin.
• Across the five-year window, Net Margin tumbled 91134 bps in 2024 and surged 4874 bps in 2025, its largest moves.
• Tracing KRYS's Net Margin over 4 years: stood at 20.63% in 2023, then soared by 142 bps to 49.9% in 2024, then fell by 4 bps to 47.98% in 2025, then grew by 0 bps to 48.06% in 2026.
• Business Quant data shows KRYS's Net Margin at 48.06% in Q1 2026, 47.98% in Q4 2025, and 81.15% in Q3 2025.